still alive & doing more swings lately in order to do a bit more of life which initially felt kinda strange to be outside during trading hours. AAOI - ACIA closed for weekend & cannot make up my mind about MYO - looking like it might head higher BUT still might close b/f eod lol Have a good weekend
LEDS on move - sold too soon on way up. Halted now @ $4.80 sheesh - that fell quick but still on watch for more
CHEK - insane move!!! thought it was done earlier & couldn't short & good thing too b/c woulda been so screwed. Popped back from $11's & caught one scalp @ $12.50 - $14.83 & then it heads over $17. Overbought & tomorrow day 3 but still will be on watch!!
Know nothing about this one & looks like pulling up some quick info not happening so will look more into it later- you in?
not in yet, but very tempting: MONMOUTH JUNCTION, N.J., April 24, 2018 - CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb®blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced first patient enrollment into the pivotal U.S. REFRESH 2-AKI trial. Focused on patients undergoing complex cardiac surgery, the REFRESH 2-AKI trial is designed to evaluate the safety and efficacy of intraoperative CytoSorb use to reduce post-operative acute kidney injury (AKI), the primary endpoint of the study. Eric Mortensen, Chief Medical Officer of CytoSorbents stated, "Achievement of the first patient enrolled is an important milestone that has occurred in parallel with the rapid expansion of our clinical operations team and final FDA Investigational Device Exemption (IDE) approval of the study. We anticipate an acceleration in the pace of the trial, with a key focus on enrollment, study execution, and onboarding new sites to our program. Dr. Eric Mortensen, Chief Medical Officer of CytoSorbents stated, "Achievement of the first patient enrolled is an important milestone that has occurred in parallel with the rapid expansion of our clinical operations team and final FDA Investigational Device Exemption (IDE) approval of the study. We anticipate an acceleration in the pace of the trial, with a key focus on enrollment, study execution, and onboarding new sites to our program."
missed pre/open but back in NVDA (only play so far). EBIO bag a bit greener but still not quite where i want it to be & to quote trumpty >"so sad" still can't short CHEK Watching JUNG & MARK.
Got a little more out of NVDA & AGMH. no position but have been watching CMG crazy & shoulda take $410.00 this morning but didn't. currently in GNPX - caught in $9's & just missed selling $15's but might get again
Got my $15's + on GNPX - almost got a double & shoulda bought more than i did!! Definite delay moving on news this morning but easy $4. for anyone that got in after my post! might have more but done playing & time for walk/gym.
Tues. 5/1: SBHGF (#1 pick 2018): $26.73 + 6% (all time high; 52 wks + 91%) blockchain for instant bank transfers -- owns $55B Ripple.
Sorry guys, I have been busy lately. I'm buying into to CVS today - might be a bit before it comes back up though.
playing other stocks today like MTP etc BUT so wish i had played IMTE - saw it shooting up & began watching around $6 - went from $2's to $21+ while posting here it came down to $17's & is now $25's - am SO paper rich right now!!!
